RWM
SCPH

Ritholtz Wealth Management’s scPharmaceuticals SCPH Stock Holding History

Ritholtz Wealth Management’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,000
Closed -$98K – 713
2022
Q3 		$98K Buy
+15,000
New +$80.1K 0.01% 687

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Ritholtz Wealth Management's SCPH Position: Q4 2022 in Review

Ritholtz Wealth Management sold out of scPharmaceuticals (SCPH) in Q4 2022, closing a stake of 15,000 shares — an estimated $98K sold.

Ritholtz Wealth Management first reported a position in SCPH in Q3 2022 and held it in 1 quarter. The position peaked at $98K in Q3 2022. 58 funds tracked by Wall St. Rank hold SCPH as of Q4 2022.

  • Ritholtz Wealth Management reported no remaining scPharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Ritholtz Wealth Management sold 15,000 scPharmaceuticals shares in Q4 2022, an estimated $98K.
  • Ritholtz Wealth Management first reported a position in scPharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Ritholtz Wealth Management's scPharmaceuticals position peaked at $98K in Q3 2022.
  • 58 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2022.

Based on Ritholtz Wealth Management's 13F filing for Q4 2022, filed 19 Jan 2023.